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BACKGROUND: Somatic mutations in phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) are frequent in breast tumours and
have been associated with oestrogen receptor (ER) expression, human epidermal growth factor receptor-2 overexpression, lymph
node metastasis and poor survival. The goal of this study was to evaluate the association between inherited variation in this oncogene
and risk of breast cancer.
METHODS: A single-nucleotide polymorphism from the PIK3CA locus that was associated with breast cancer in a study of Caucasian
breast cancer cases and controls from the Mayo Clinic (MCBCS) was genotyped in 5436 cases and 5280 controls from the Cancer
Genetic Markers of Susceptibility (CGEMS) study and in 30 949 cases and 29 788 controls from the Breast Cancer Association
Consortium (BCAC).
RESULTS: Rs1607237 was significantly associated with a decreased risk of breast cancer in MCBCS, CGEMS and all studies of white
Europeans combined (odds ratio (OR)¼ 0.97, 95% confidence interval (CI) 0.95–0.99, P¼ 4.6 103), but did not reach
significance in the BCAC replication study alone (OR¼ 0.98, 95% CI 0.96–1.01, P¼ 0.139).
CONCLUSION: Common germline variation in PIK3CA does not have a strong influence on the risk of breast cancer
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Phosphatidylinositol-3 kinases (PI3Ks) constitute a lipid kinase
family integral to signalling pathways that regulate many cancer-
related processes, including cell proliferation, adhesion, apoptosis,
survival and motility (Fruman et al, 1998; Cantley, 2002).
Alteration of PI3K family members, such as amplification of the
phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) onco-
gene on chromosome 3q26 that encodes the p110a catalytic
subunit of PI3K, are commonly observed in human cancers.
Amplification and overexpression of PIK3CA results in increased
production of the phosphatidylinositol-3,4,5-triphosphate second
messenger, hyperactivation of the PI3K/AKT pathway, and
stimulation of cellular transformation and tumour progression
(Shayesteh et al, 1999; Ma et al, 2000; Fresno Vara et al, 2004; Saal
et al, 2005; Samuels and Ericson, 2006). Somatic mutations in
PIK3CA are also common in colon (18–32%), gastric (4–25%),
endometrial (36%), liver (36%), brain (27%) and breast (18–40%)
tumours (Bachman et al, 2004; Campbell et al, 2004; Samuels et al,
2004; Karakas et al, 2006; Ligresti et al, 2009). Functional analyses
have shown that many of these mutations activate PIK3CA
enzymatic activity and stimulate downstream AKT signalling,
promoting growth factor-independent growth and metastasis
(Samuels et al, 2004; Samuels and Ericson, 2006).
In breast tumours, PIK3CA mutations have been consistently
associated with ER-positive and human epidermal growth factor
receptor-2 (HER2)-positive tumour status (Saal et al, 2005; Li et al,
2006; Perez-Tenorio et al, 2007; Stemke-Hale et al, 2008)
(Saal et al, 2005; Perez-Tenorio et al, 2007). The correlation
between these mutations and breast cancer prognosis is less clear,
with several studies reporting associations between PIK3CA
mutations and lymph node metastasis and worse overall and
breast cancer-specific survival (Saal et al, 2005; Li et al, 2006; Lai
et al, 2008; Aleskandarany et al, 2010), whereas other studies have
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reported associations with longer survival particularly among
patients with ER-positive, HER2-negative tumours (Perez-Tenorio
et al, 2007; Kalinsky et al, 2009; Loi et al, 2010).
Although the pathological and clinical significance of PIK3CA
somatic mutations has been well studied, the contribution of
inherited variation in this important oncogene to risk of breast
cancer is unknown. Here we investigated the influence of germline
variation in PIK3CA on breast cancer risk.
MATERIALS AND METHODS
Mayo clinic breast cancer study
The details of the Mayo Clinic Breast Cancer case–control Study
(MCBCS) have been described previously (Wang et al, 2008).
Briefly, cases were comprised of Caucasian women with invasive
breast cancer diagnosed within 6 months of ascertainment with no
prior history of cancer. Controls were comprised of Caucasian
women visiting the Mayo Clinic for general medical exams in the
Department of Internal Medicine with no prior history of cancer.
Participants were recruited under an Institutional Review Board
approved protocol. A total of 798 cases and 843 controls were
utilised for stage 1 genotyping (Table 1).
Replication studies
The Cancer Genetic Markers of Susceptibility (CGEMS) breast
cancer case–control study and 26 case–control studies from
Breast Cancer Association Consortium (BCAC) contributed data to
these analyses (described in Supplementary Table 1). Stage 1 of the
CGEMS GWAS included 1145 cases and 1142 controls of self-
reported white European ancestry (Thomas et al, 2009), whereas
the combined Stage 1 and 2 of CGEMS included a total of 5436
cases and 5280 controls (Table 1). The BCAC replication was
comprised of 24 studies of women of primarily European descent
(Supplementary Table 1), 1702 additional samples from MCBCS
and two studies (SEBCS and TBCS) of women from Southeast Asia
(Table 1). Final combined analyses included 35 991 breast cancer
cases and 35 153 controls of white European ancestry, as well as
2183 breast cancer cases and 1469 controls of Asian ancestry.
Study participants were recruited under protocols approved by the
institutional review board at each institution and all subjects
provided written informed consent.
Genotyping
Four haplotype-tagging single-nucleotide polymorphisms (SNPs)
within PIK3CA (rs13320527, rs3729692, rs1607237, rs9838117)
were selected (r240.80 in European–American genotype data
from HapMap release 21). A total of 1741 Mayo Clinic samples
(798 cases, 843 controls and 100 duplicates) were genotyped on
custom oligo pool assays at Illumina Corporation (San Diego, CA,
USA) using the Illumina GoldenGate assay. All SNPs had genotype
call rates495%. Concordance between duplicate samples was 100%.
Genotyping of rs1607237 in CGEMS and BCAC was performed using
a TaqMan allelic discrimination assay or the Sequenom platform
(Sequenom, San Diego, CA, USA) via standard protocols. Genotyp-
ing concordance was verified with internal duplicates and overall
data quality was ensured using independent genotyping of 96 CEU
samples by each genotyping center (Garcia-Closas et al, 2008). All
studies met the specified criteria for call rate (495%).
Pathology and tumour markers
The collection of pathology and tumour marker information for
BCAC has been described previously (Yang et al, 2011). Pathology
data were also available for 900 CGEMS subjects. Briefly, studies
provided information on histopathological subtype, grade of
differentiation, tumour size, nodal involvement and stage at
diagnosis of breast tumours. All studies except BBCS, GC-HBOC
and HMBCS provided data on ER and progesterone receptor (PR)
status of tumours, and 12 studies provided data on HER2
(Supplementary Table 2). ER/PR status was most commonly
defined using data from medical records. Oestrogen receptor and
PR negative status was defined as o10% of the tumour cells
stained. Human epidermal growth factor receptor-2-negative
status was typically defined as a score of 0 or 1þ on a HER2
immunohistochemistry (IHC) scale of 0–3þ .
Statistical methods
Evidence of departure from Hardy–Weinberg equilibrium (HWE)
was assessed in controls using a goodness of fit test and none
was observed (HWE PX0.001). Single-nucleotide polymorphism
associations were tested using unconditional logistic regression
adjusting for age and state of residence in a log-additive model.
We also calculated odds ratios (ORs) and 95% confidence intervals
(CIs) separately for heterozygotes and rare homozygotes.
The association between rs1607237 and breast cancer risk in stage
1 of the CGEMS GWAS was evaluated as previously described
(Thomas et al, 2009). Associations with breast cancer risk in the
BCAC studies and the combined BCAC, MCBCS and CGEMS
studies were evaluated using unconditional logistic regression
adjusting for study center. A likelihood ratio test of heterogeneity
by age groups was not significant (P¼ 0.10), and further
adjustment for age did not change the results. Analyses of
pathology-specific subsets of cases were conducted using poly-
tomous regression with controls as the reference outcome,
adjusting for study site.
Table 1 Studies contributing to evaluation of associations between
rs1607237 and breast cancer risk
Studya Country Cases n (%) Controls n (%)
ABCFS Australia 1199 (3.1) 438 (1.2)
ABCS The Netherlands 1465 (3.8) 548 (1.5)
BBCC Germany 1060 (2.8) 994 (2.7)
BBCS UK 1153 (3.0) 831 (2.3)
BIGGS Ireland 1060 (2.8) 900 (2.5)
CGEMSb USA 5436 (14.2) 5280 (14.4)
CNIO-BCS Spain 752 (2.0) 823 (2.2)
GC-HBOC Germany 864 (2.3) 1224 (3.3)
GENICA Germany 1013 (2.7) 1012 (2.8)
GESBC Germany 563 (1.5) 564 (1.5)
HABCS Germany 1046 (2.7) 998 (2.7)
HMBCS Belarus 1760 (4.6) 1015 (2.8)
KARBAC Sweden 812 (2.1) 863 (2.4)
kConFab/AOCS Australia/New Zealand 566 (1.5) 899 (2.5)
KBCP Finland 485 (1.3) 427 (1.2)
MARIE Germany 2754 (7.2) 5302 (14.5)
MBCSG Italy 739 (1.9) 1231 (3.4)
MCBCSc USA 1789 (4.7) 1554 (4.2)
MCCS Australia 679 (1.8) 751 (2.1)
NC-BCFR USA 388 (1.0) 154 (0.4)
OBCS Finland 544 (1.4) 509 (1.4)
OFBCR Canada 1170 (3.1) 329 (0.9)
SBCS UK 1217 (3.2) 1201 (3.3)
SEARCH UK 6520 (17.1) 6779 (18.5)
SEBCSd Korea 1732 (4.5) 1178 (3.2)
TBCSd Thailand 451 (1.2) 291 (0.8)
UCIBCS USA 957 (2.5) 527 (1.4)
Total 38 174 (100) 36 622 (100)
aSee Supplementary Table 1 for definition of study acronyms. bStage 2: Cancer
Genetic Markers of Susceptibility study. cIncludes Stage 1: Mayo Clinic Breast Cancer
Study. dAsian case–control studies.
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RESULTS
Of four PIK3CA haplotype-tagging SNPs, rs1607237 was signifi-
cantly associated with risk of breast cancer in MCBCS (OR¼ 0.85,
95% CI 0.73–0.98, P¼ 0.023; Table 2, Supplementary Figure 1).
Next we evaluated associations between rs1607237 and breast
cancer risk in 1145 cases and 1142 controls genotyped in stage 1 of
the CGEMS breast cancer GWAS (Thomas et al, 2009). Rs1607237
was significantly associated with breast cancer risk (heterozygous
OR¼ 1.12, homozygous OR¼ 0.79, score P¼ 0.017). To provide a
more stable estimate of risk in this population, 8429 additional
CGEMS subjects were genotyped for rs1607237. In all 5436 cases
and 5280 controls from stage 1 and 2 of CGEMS, rs1607237 was
strongly associated with a decrease in breast cancer risk
(OR¼ 0.92, 95% CI 0.88–0.98, P¼ 0.0050; Table 2).
This finding provided the rationale for further evaluation of this
SNP in 23 BCAC studies involving women of European ancestry
(28 766 cases, 28 319 controls), and two BCAC studies of Asian
women (2183 cases, 1469 controls; Table 1). Rs1607237 was not
significantly associated with breast cancer risk in the 23 BCAC
studies of women of European ancestry (OR¼ 0.98, 95% CI 0.96–
1.01, P¼ 0.139) or in the two Asian BCAC studies (OR¼ 1.05, 95%
CI 0.94–1.16, P¼ 0.39; Table 2). However, when combining all
genotype data from the three stages of this study (MCBCS, CGEMS
and BCAC; Supplementary Table 3), rs1607237 was significantly
associated with risk of breast cancer (OR¼ 0.97, 95% CI 0.95–0.99,
P¼ 9.5 103). Similarly, a significant association was observed
when considering only women of European ancestry in the
combined analysis (OR¼ 0.97, 95% CI 0.95–0.99, P¼ 4.6 103;
(Table 2). There was no evidence of heterogeneity by study site
among the 25 Caucasian studies (P¼ 0.14; Supplementary Figure 2).
To further understand the association with breast cancer, we
restricted the analysis to women with invasive breast cancer.
Rs1607237 was associated with a reduced risk of invasive breast
cancer (OR¼ 0.97, 95% CI 0.95–0.99, P¼ 0.012; Table 2), whereas
no association with risk of ductal carcinoma in situ was observed
(OR¼ 0.93, 95% CI 0.85–1.02, P¼ 0.12). In addition, we explored
differences in PIK3CA SNP associations in the combined data set
by tumour subtype (Supplementary Table 4). The rs1607237
variant was not associated with any subtypes defined by ER, PR or
HER2 status, although it is important to note the reduction in
sample size when restricting to these tumour subtypes.
DISCUSSION
Here we report an association between inherited variation in the
oncogene PIK3CA and risk of breast cancer in a large, three-stage
analysis utilising nearly 75 000 subjects from 27 case–control
study studies. We show that rs1607237 is significantly associated
with a small decrease in breast cancer risk (OR¼ 0.97, 95% CI
0.95–0.99, P¼ 9.5 103) in all studies combined and when
considering only women of European ancestry in the combined
studies (OR¼ 0.97, 95% CI 0.95–0.99, P¼ 4.6 103). However,
the association did not achieve significance in the large third stage
involving only BCAC studies. Although the first two stages of our
analysis suggest an association between PIK3CA and breast cancer
risk, our inability to confirm this finding in the BCAC studies
suggests that the result should be interpreted with caution.
We further explored the linkage disequilibrium patterns in the
PIK3CA coding and promoter regions to better understand the
relationship between rs1607237 and other variation in this region.
Rs1607237 was not in strong linkage disequilibrium with two non-
synonymous polymorphic variants in the coding region of
PIK3CA, rs1051399 (r2¼ 0.0060) and rs3729680 (r2¼ 0.034), which
had been genotyped in HapMap samples of European ancestry.
However, an additional 18 non-synonymous variants were either
not polymorphic or had not been genotyped in the HapMap
samples, making inference about the relationship between
rs1607237 and all variants of unknown significance in the PIK3CA
coding region difficult. In addition, two PIK3CA promoter SNPs
were in low LD with rs1607237 (rs9831234, r2¼ 0.16; rs2865084,
r2¼ 0.038). However, it remains possible that PIK3CA promoter
SNPs that were not captured in this study are related to breast
cancer risk.
It is also important to note that the effect estimate for rs1607237
in the BCAC replication studies and in the overall BCAC, MCBCS
and CGEMS studies is quite small (OR¼ 0.97). This limits our
statistical power to detect significant associations in these studies
despite the large sample size, particularly in analyses utilising
pathology information that is available for only a subset of
subjects. Similarly, we had limited power to detect associations in
the original MCBCS study with the three non-significant PIK3CA
SNPs. Thus, it remains possible that evaluation of these variants in
the larger BCAC cohort might detect associations with risk. While
the effect of rs1607237 on risk is small, the association between
inherited variation in this important oncogene and breast cancer
risk does provide valuable biological insight into the development
of this disease. Validation of rs1607237 in GWAS studies from
other large collaborative groups and additional studies by BCAC
with detailed pathology information are necessary to confirm this
association. Functional evaluation of this variant is needed to fully
understand the relationship between inherited PIK3CA variation
and breast cancer risk.
ACKNOWLEDGEMENTS
The ABCS study was funded by the Dutch Cancer Society (grants
NKI 2001-2423; NKI 2007-3839), the Dutch National Genomics
Table 2 Associations between rs1607237 and breast cancer in MCBCS, CGEMS and BCAC
2-d.f. model
Log-additive model Heterozygous Homozygous
Cases Controls OR (95% CI) P-value OR (95% CI) OR (95% CI)
Stage 1: MCBCS 798 843 0.85 (0.73–0.98) 0.023 0.75 (0.60–0.93) 0.76 (0.57–1.01)
Stage 2: CGEMS 5436 5280 0.92 (0.88–0.98) 0.0050 1.00 (0.92–1.09) 0.82 (0.73–0.92)
Stage 3: BCAC 28 766 28 319 0.98 (0.96–1.01) 0.139 0.96 (0.93–1.00) 0.97 (0.92–1.02)
Combined analysis 35 991 35 153 0.97 (0.95–0.99) 0.0046 0.97 (0.93–1.00) 0.94 (0.90–0.98)
Invasive 33 660 34 988 0.97 (0.95–0.99) 0.012 0.97 (0.94–1.00) 0.95 (0.90–0.99)
DCIS 1159 16 889 0.93 (0.85–1.02) 0.12 0.98 (0.85–1.12) 0.84 (0.70–1.02)
Abbreviations: BCAC¼ Breast Cancer Association Consortium; CGEMS¼Cancer Genetic Markers of Susceptibility; CI¼ confidence interval; DCIS¼ ductal carcinoma in situ;
MCBCS¼Mayo Clinic breast cancer case–control study; OR¼ odds ratio.
PIK3CA common variants and breast cancer risk
KN Stevens et al
1937
British Journal of Cancer (2011) 105(12), 1934 – 1939& 2011 Cancer Research UK
G
e
n
e
ti
c
s
a
n
d
G
e
n
o
m
ic
s
Initiative; ABCS acknowledges all patients, and Sten Cornelissen,
Richard van Hien, Flora van Leeuwen, Vincent Smit and other
contributors to the ‘BOSOM’ study (ABCS). The ABCFS, NC-BCFR
and OFBCR works were supported by the United States National
Cancer Institute, National Institutes of Health (NIH) under RFA-
CA-06-503 and through cooperative agreements with members of
the Breast Cancer Family Registry (BCFR) and Principal Investi-
gators, including Cancer Care Ontario (U01 CA69467), Northern
California Cancer Center (U01 CA69417), University of Melbourne
(U01 CA69638). Samples from the NC-BCFR were processed and
distributed by the Coriell Institute for Medical Research. The
content of this manuscript does not necessarily reflect the views or
policies of the National Cancer Institute or any of the collaborating
centers in the BCFR, nor does mention of trade names, commercial
products or organisations imply endorsement by the US Govern-
ment or the BCFR. The ABCFS was also supported by the National
Health and Medical Research Council of Australia, the New South
Wales Cancer Council, the Victorian Health Promotion Founda-
tion (Australia) and the Victorian Breast Cancer Research
Consortium. JLH is a National Health and Medical Research
Council (NHMRC) Australia Fellow and a Victorian Breast Cancer
Research Consortium Group Leader. MCS is a NHMRC Senior
Research Fellow and a Victorian Breast Cancer Research
Consortium Group Leader. BBCC is funded in part by the ELAN
fund of the University Hospital Erlangen. The BBCS is funded by
Cancer Research UK and Breakthrough Breast Cancer and
acknowledges NHS funding to the NIHR Biomedical Research
Centre, and the National Cancer Research Network (NCRN). ES is
supported by NIHR Comprehensive Biomedical Research Centre,
Guy’s & St Thomas’ NHS Foundation Trust in partnership with
King’s College London, United Kingdom. IT is supported by the
Oxford Biomedical Research Centre. The CNIO-BCS was sup-
ported by the Genome Spain Foundation, the Red Tema´tica de
Investigacio´n Cooperativa en Ca´ncer and grants from the
Asociacio´n Espan˜ola Contra el Ca´ncer and the Fondo de
Investigacio´n Sanitario (PI081583 and PI081120). We thank Charo
Alonso, Tais Moreno, Guillermo Pita, Primitiva Mene´ndez and
Pilar Zamora for their contribution to this work. The GC-HBOC
was collected within a project funded by the Deutsche Krebshilfe
(Grant number: 107054). It was supported by the Dietmar-Hopp
Foundation, the Helmholtz society and the German Cancer
Research Center (DKFZ). We thank Sandrine Tchatchou for
genotyping. The HABCS was supported by an intramural grant
from Hannover Medical School. The HMBCS was supported by
short-term fellowships from the German Academic Exchange
Program (to NB), and the Friends of Hannover Medical School (to
NB). KARBAC acknowledges The Swedish Cancer Society and The
Stockholm Cancer Society. KBCP is supported by grants from the
Finnish Cancer Society; the Academy of Finland (grant number
127220); the special Government Funding (EVO) of Kuopio
University Hospital (grant number 5654113 and 5501) and by
the strategic funding of the University of Eastern Finland. We
thank Mrs Helena Kemila¨inen, Mrs Aija Parkkinen and Mrs Eija
Myo¨ha¨nen for their skillful technical assistance. We thank Heather
Thorne, Eveline Niedermayr, all the kConFab research nurses and
staff, the heads and staff of the Family Cancer Clinics, and the
Clinical Follow Up Study (funded 2001–2009 by NHMRC and
currently by the National Breast Cancer Foundation and Cancer
Australia #628333) for their contributions to this resource, and the
many families who contribute to kConFab. kConFab is supported
by grants from the National Breast Cancer Foundation, the
National Health and Medical Research Council (NHMRC) and by
the Queensland Cancer Fund, the Cancer Councils of New South
Wales, Victoria, Tasmania and South Australia, and the Cancer
Foundation of Western Australia Financial support for the AOCS
was provided by the United States Army Medical Research and
Materiel Command (DAMD17-01-1-0729); the Cancer Council of
Tasmania and Cancer Foundation of Western Australia; and the
NHMRC [199600]. GC-T is supported by the NHMRC. PP is
supported by funds from Italian citizens who allocated the
5 1000 share of their tax payment to the Fondazione IRCCS
Istituto Nazionale Tumori, according to Italian laws (INT-
Institutional strategic projects ‘5 1000’). MBCSG thanks Paolo
Radice, Bernard Peissel, Daniela Zaffaroni and Marco A Pierotti of
the Fondazione IRCCS Istituto Nazionale Tumori and Monica
Barile of the Istituto Europeo di Oncologia, Milano, Italy. MCBCS
was supported by NIH grant CA122340 and US Recovery act award
CA122340Z. Many people have contributed to the MCCS, including
the original investigators and the diligent teams who recruited the
participants and who continue working on follow-up. Finally, we
express our gratitude to the many thousands of Melbourne
residents who continue to participate in the study. Cohort
recruitment was funded by VicHealth and Cancer Council Victoria.
The MCCS was further supported by Australian NHMRC grants
209057, 251553 and 504711 and by infrastructure provided by
Cancer Council Victoria. OBCS was supported by research grants
from the Finnish Cancer Foundation, the Sigrid Juselius Founda-
tion, the Academy of Finland, the University of Oulu and the Oulu
University Hospital. SBCS was funded by the Breast Cancer
Campaign and Yorkshire Cancer Research. The authors acknowl-
edge Helen Cramp, Sue Higham, Dan Connley, Saba Balasubra-
manian. The UCIBCS is supported by the National Institutes of
Health, National Cancer Institute grants CA-58860, CA-92044 and
the Lon V Smith Foundation grant LVS-39420.
Conflict of interest
The authors declare no conflict of interest.
Supplementary Information accompanies the paper on British
Journal of Cancer website (http://www.nature.com/bjc)
REFERENCES
Aleskandarany MA, Rakha EA, Ahmed MA, Powe DG, Paish EC,
Macmillan RD, Ellis IO, Green AR (2010) PIK3CA expression in invasive
breast cancer: a biomarker of poor prognosis. Breast Cancer Res Treat
122(1): 45–53
Bachman KE, Argani P, Samuels Y, Silliman N, Ptak J, Szabo S, Konishi H,
Karakas B, Blair BG, Lin C, Peters BA, Velculescu VE, Park BH (2004)
The PIK3CA gene is mutated with high frequency in human breast
cancers. Cancer Biol Ther 3(8): 772–775
Campbell IG, Russell SE, Choong DY, Montgomery KG, Ciavarella ML,
Hooi CS, Cristiano BE, Pearson RB, Phillips WA (2004) Mutation of the
PIK3CA gene in ovarian and breast cancer. Cancer Res 64(21): 7678–7681
Cantley LC (2002) The phosphoinositide 3-kinase pathway. Science
296(5573): 1655–1657
Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C,
Gonzalez-Baron M (2004) PI3K/Akt signalling pathway and cancer.
Cancer Treat Rev 30(2): 193–204
Fruman DA, Meyers RE, Cantley LC (1998) Phosphoinositide kinases. Annu
Rev Biochem 67: 481–507
Garcia-Closas M, Hall P, Nevanlinna H, Pooley K, Morrison J, Richesson
DA, Bojesen SE, Nordestgaard BG, Axelsson CK, Arias JI, Milne RL,
Ribas G, Gonzalez-Neira A, Benitez J, Zamora P, Brauch H, Justenhoven
C, Hamann U, Ko YD, Bruening T, Haas S, Dork T, Schurmann P,
Hillemanns P, Bogdanova N, Bremer M, Karstens JH, Fagerholm R,
Aaltonen K, Aittomaki K, von Smitten K, Blomqvist C, Mannermaa A,
Uusitupa M, Eskelinen M, Tengstrom M, Kosma VM, Kataja V,
Chenevix-Trench G, Spurdle AB, Beesley J, Chen X, Devilee P, van
PIK3CA common variants and breast cancer risk
KN Stevens et al
1938
British Journal of Cancer (2011) 105(12), 1934 – 1939 & 2011 Cancer Research UK
G
e
n
e
tic
s
a
n
d
G
e
n
o
m
ic
s
Asperen CJ, Jacobi CE, Tollenaar RA, Huijts PE, Klijn JG, Chang-Claude J,
Kropp S, Slanger T, Flesch-Janys D, Mutschelknauss E, Salazar R, Wang-
Gohrke S, Couch F, Goode EL, Olson JE, Vachon C, Fredericksen ZS,
Giles GG, Baglietto L, Severi G, Hopper JL, English DR, Southey MC,
Haiman CA, Henderson BE, Kolonel LN, Le Marchand L, Stram DO,
Hunter DJ, Hankinson SE, Cox DG, Tamimi R, Kraft P, Sherman ME,
Chanock SJ, Lissowska J, Brinton LA, Peplonska B, Hooning MJ, Meijers-
Heijboer H, Collee JM, van den Ouweland A, Uitterlinden AG, Liu J, Lin
LY, Yuqing L, Humphreys K, Czene K, Cox A, Balasubramanian SP,
Cross SS, Reed MW, Blows F, Driver K, Dunning A, Tyrer J, Ponder BA,
Sangrajrang S, Brennan P, McKay J, Odefrey F, Gabrieau V, Sigurdson A,
Doody M, Struewing JP, Alexander B, Easton DF, Pharoah PD (2008)
Heterogeneity of breast cancer associations with five susceptibility loci
by clinical and pathological characteristics. PLoS Genet 4(4): e1000054
Kalinsky K, Jacks LM, Heguy A, Patil S, Drobnjak M, Bhanot UK, Hedvat
CV, Traina TA, Solit D, Gerald W, Moynahan ME (2009) PIK3CA
mutation associates with improved outcome in breast cancer. Clin
Cancer Res 15(16): 5049–5059
Karakas B, Bachman KE, Park BH (2006) Mutation of the PIK3CA oncogene
in human cancers. Br J Cancer 94(4): 455–459
Lai YL, Mau BL, Cheng WH, Chen HM, Chiu HH, Tzen CY (2008) PIK3CA
exon 20 mutation is independently associated with a poor prognosis in
breast cancer patients. Ann Surg Oncol 15(4): 1064–1069
Li SY, Rong M, Grieu F, Iacopetta B (2006) PIK3CA mutations in breast cancer
are associated with poor outcome. Breast Cancer Res Treat 96(1): 91–95
Ligresti G, Militello L, Steelman LS, Cavallaro A, Basile F, Nicoletti F, Stivala
F, McCubrey JA, Libra M (2009) PIK3CA mutations in human solid
tumors: role in sensitivity to various therapeutic approaches. Cell Cycle
8(9): 1352–1358
Loi S, Haibe-Kains B, Majjaj S, Lallemand F, Durbecq V, Larsimont D,
Gonzalez-Angulo AM, Pusztai L, Symmans WF, Bardelli A, Ellis P, Tutt AN,
Gillett CE, Hennessy BT, Mills GB, Phillips WA, Piccart MJ, Speed TP,
McArthur GA, Sotiriou C (2010) PIK3CA mutations associated with gene
signature of low mTORC1 signaling and better outcomes in estrogen receptor-
positive breast cancer. Proc Natl Acad Sci USA 107(22): 10208–10213
Ma YY, Wei SJ, Lin YC, Lung JC, Chang TC, Whang-Peng J, Liu JM, Yang
DM, Yang WK, Shen CY (2000) PIK3CA as an oncogene in cervical
cancer. Oncogene 19(23): 2739–2744
Perez-Tenorio G, Alkhori L, Olsson B, Waltersson MA, Nordenskjold B,
Rutqvist LE, Skoog L, Stal O (2007) PIK3CA mutations and PTEN loss
correlate with similar prognostic factors and are not mutually exclusive
in breast cancer. Clin Cancer Res 13(12): 3577–3584
Saal LH, Holm K, Maurer M, Memeo L, Su T, Wang X, Yu JS, Malmstrom
PO, Mansukhani M, Enoksson J, Hibshoosh H, Borg A, Parsons R (2005)
PIK3CA mutations correlate with hormone receptors, node metastasis,
and ERBB2, and are mutually exclusive with PTEN loss in human breast
carcinoma. Cancer Res 65(7): 2554–2559
Samuels Y, Ericson K (2006) Oncogenic PI3K and its role in cancer. Curr
Opin Oncol 18(1): 77–82
Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar
A, Powell SM, Riggins GJ, Willson JK, Markowitz S, Kinzler KW,
Vogelstein B, Velculescu VE (2004) High frequency of mutations of the
PIK3CA gene in human cancers. Science 304(5670): 554
Shayesteh L, Lu Y, Kuo WL, Baldocchi R, Godfrey T, Collins C, Pinkel D,
Powell B, Mills GB, Gray JW (1999) PIK3CA is implicated as an oncogene
in ovarian cancer. Nat Genet 21(1): 99–102
Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies
M, Carey M, Hu Z, Guan Y, Sahin A, Symmans WF, Pusztai L, Nolden
LK, Horlings H, Berns K, Hung MC, van de Vijver MJ, Valero V, Gray
JW, Bernards R, Mills GB, Hennessy BT (2008) An integrative genomic
and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast
cancer. Cancer Res 68(15): 6084–6091
Thomas G, Jacobs KB, Kraft P, Yeager M, Wacholder S, Cox DG, Hankinson
SE, Hutchinson A, Wang Z, Yu K, Chatterjee N, Garcia-Closas M,
Gonzalez-Bosquet J, Prokunina-Olsson L, Orr N, Willett WC, Colditz GA,
Ziegler RG, Berg CD, Buys SS, McCarty CA, Feigelson HS, Calle EE, Thun
MJ, Diver R, Prentice R, Jackson R, Kooperberg C, Chlebowski R,
Lissowska J, Peplonska B, Brinton LA, Sigurdson A, Doody M, Bhatti P,
Alexander BH, Buring J, Lee IM, Vatten LJ, Hveem K, Kumle M, Hayes
RB, Tucker M, Gerhard DS, Fraumeni Jr JF, Hoover RN, Chanock SJ,
Hunter DJ (2009) A multistage genome-wide association study in breast
cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1).
Nat Genet 41(5): 579–584
Wang X, Goode EL, Fredericksen ZS, Vierkant RA, Pankratz VS, Liu-Mares
W, Rider DN, Vachon CM, Cerhan JR, Olson JE, Couch FJ (2008)
Association of genetic variation in genes implicated in the beta-catenin
destruction complex with risk of breast cancer. Cancer Epidemiol
Biomarkers Prev 17(8): 2101–2108
Yang XR, Chang-Claude J, Goode EL, Couch FJ, Nevanlinna H, Milne RL,
Gaudet M, Schmidt MK, Broeks A, Cox A, Fasching PA, Hein R, Spurdle
AB, Blows F, Driver K, Flesch-Janys D, Heinz J, Sinn P, Vrieling A,
Heikkinen T, Aittomaki K, Heikkila P, Blomqvist C, Lissowska J,
Peplonska B, Chanock S, Figueroa J, Brinton L, Hall P, Czene K,
Humphreys K, Darabi H, Liu J, Van ‘t Veer LJ, van Leeuwen FE, Andrulis
IL, Glendon G, Knight JA, Mulligan AM, O’Malley FP, Weerasooriya N,
John EM, Beckmann MW, Hartmann A, Weihbrecht SB, Wachter DL, Jud
SM, Loehberg CR, Baglietto L, English DR, Giles GG, McLean CA,
Severi G, Lambrechts D, Vandorpe T, Weltens C, Paridaens R, Smeets A,
Neven P, Wildiers H, Wang X, Olson JE, Cafourek V, Fredericksen Z,
Kosel M, Vachon C, Cramp HE, Connley D, Cross SS, Balasubramanian
SP, Reed MW, Dork T, Bremer M, Meyer A, Karstens JH, Ay A, Park-
Simon TW, Hillemanns P, Arias Perez JI, Menendez Rodriguez P,
Zamora P, Benitez J, Ko YD, Fischer HP, Hamann U, Pesch B, Bruning T,
Justenhoven C, Brauch H, Eccles DM, Tapper WJ, Gerty SM, Sawyer EJ,
Tomlinson IP, Jones A, Kerin M, Miller N, McInerney N, Anton-Culver
H, Ziogas A, Shen CY, Hsiung CN, Wu PE, Yang SL, Yu JC, Chen ST, Hsu
GC, Haiman CA, Henderson BE, Le Marchand L, Kolonel LN, Lindblom
A, Margolin S, Jakubowska A, Lubinski J, Huzarski T, Byrski T, Gorski B,
Gronwald J, Hooning MJ, Hollestelle A, van den Ouweland AM, Jager A,
Kriege M, Tilanus-Linthorst MM, Collee M, Wang-Gohrke S, Pylkas K,
Jukkola-Vuorinen A, Mononen K, Grip M, Hirvikoski P, Winqvist R,
Mannermaa A, Kosma VM, Kauppinen J, Kataja V, Auvinen P, Soini Y,
Sironen R, Bojesen SE, Orsted DD, Kaur-Knudsen D, Flyger H,
Nordestgaard BG, Holland H, Chenevix-Trench G, Manoukian S, Barile
M, Radice P, Hankinson SE, Hunter DJ, Tamimi R, Sangrajrang S,
Brennan P, McKay J, Odefrey F, Gaborieau V, Devilee P, Huijts PE,
Tollenaar RA, Seynaeve C, Dite GS, Apicella C, Hopper JL, Hammet F,
Tsimiklis H, Smith LD, Southey MC, Humphreys MK, Easton D, Pharoah
P, Sherman ME, Garcia-Closas M (2011) Associations of breast
cancer risk factors with tumor subtypes: a pooled analysis from the
Breast Cancer Association Consortium studies. J Natl Cancer Inst 103(3):
250–263
APPENDIX
The GENICA Network
Gene Environment Interaction and Breast Cancer in Germany
(GENICA): Dr. Margarete Fischer-Bosch-Institute of Clinical
Pharmacology, Stuttgart, and University Tu¨bingen, Germany
(Hiltrud Brauch, Christina Justenhoven); Molecular Genetics of
Breast Cancer, Deutsches Krebsforschungszentrum (DKFZ), Hei-
delberg, Germany (UH); Department of Internal Medicine,
Evangelische Kliniken Bonn gGmbH, Johanniter Krankenhaus,
Bonn, Germany (YDK, Christian Baisch); Institute of Pathology,
Medical Faculty of the University of Bonn, Germany (Hans-Peter
Fischer); Institute for Prevention and Occupational Medicine of
the German Social Accident Insurance (IPA), Bochum, Germany
(TB, Beate Pesch, Volker Harth, Sylvia Rabstein). The GENICA was
funded by the Federal Ministry of Education and Research (BMBF)
Germany grants 01KW9975/5, 01KW9976/8, 01KW9977/0 and
01KW0114, the Robert Bosch Foundation, Stuttgart, Deutsches
Krebsforschungszentrum (DKFZ), Heidelberg, Institute for Pre-
vention and Occupational Medicine of the German Social Accident
Insurance (IPA), Bochum, as well as the Department of Internal
Medicine, Evangelische Kliniken Bonn gGmbH, Johanniter Kran-
kenhaus, Bonn, Germany.
kConFab Investigators, Australian Ovarian Cancer Study Group
Peter MacCallum Cancer Centre, St Andrews Place, East
Melbourne VIC 3002, Australia.
This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the
license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License.
PIK3CA common variants and breast cancer risk
KN Stevens et al
1939
British Journal of Cancer (2011) 105(12), 1934 – 1939& 2011 Cancer Research UK
G
e
n
e
ti
c
s
a
n
d
G
e
n
o
m
ic
s
